A unique delivery process could mean faster, cheaper and more effective vaccination procedures.
A unique delivery process could mean faster, cheaper and more effective vaccination procedures. Instead of using the disease organism itself, which all conventional vaccines rely on, the new technology uses bacterial viruses called 'bacteriophage' that contain DNA. The DNA vaccine is placed inside the bacteriophage with special instructions so that the vaccinated host can make the vaccine by reading the DNA.
Big DNA Ltd, a spin out company from the Moredun Research Institute in Edinburgh (UK), has been created to develop and commercialize the technology. Dr John March, creator of the company, says: "We couldn't have taken the development of this process further, without spinning out the technology, patents and processes from the research establishment and creating Big DNA Ltd as a commercial firm to do it. The potential here is enormous and I am passionate about getting this process to become a reality."
Bacteriophage have many advantages. Conventional vaccines are difficult and expensive to make, require specialist facilities and expertise, and sometimes fail to work for certain diseases. Bacteriophage cannot cause the disease they are immunizing against and can also be taken orally, either in liquid or tablet form, eliminating the need for needles and injections, and all their associated hazards.
March concludes: "This cheap and effective way of developing and delivering vaccines has enormous importance for public health in the future."
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.